Literature DB >> 8100352

Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20.

L L Demchyshyn1, C B Srikant, R K Sunahara, G Kent, P Seeman, H H Van Tol, R Panetta, Y C Patel, H B Niznik.   

Abstract

Based on pharmacological, biochemical, and molecular criteria, multiple somatostatin receptor (SSTR) subtypes selective for somatostatin (SST)-14 and -28 have been postulated to exist in both the brain and periphery. We report here on the cloning and characterization of a human gene encoding a new member of the guanine nucleotide-binding protein-linked SSTR family, termed human (h)SSTR4. The 388-amino acid protein, with a predicted molecular mass of approximately 42 kDa, displays sequence similarity, particularly within putative transmembrane domains, with the recently cloned hSSTR1 (69%), hSSTR2 (56%), and hSSTR3 (58%). Membranes prepared from COS-7 cells transiently expressing the hSSTR4 gene bound 125I-[Leu8,D-Trp22,Tyr25]SST-28 in a saturable manner with high affinity (approximately 60 pM) and with a pharmacological profile and rank order of potency ([D-Trp8]SST-14 > SST-14 > SMS 201-995 > SST-28 > MK-678) indicative of a SST-14-selective receptor. Ki values for the inhibition of 125I-[Leu8,D-Trp22,Tyr25]SST-28 binding to the expressed receptor by these somatostatinergic peptides were 0.3, 1.1, 1.4, 2.2, and 6.5 nM, respectively. High affinity agonist binding to hSSTR4 was significantly reduced by GTP and pertussis toxin, indicating association of the expressed receptor with pertussis toxin-sensitive guanine nucleotide-binding proteins. Northern blot analysis revealed the presence of an SSTR4 mRNA species of approximately 4 kilobases in select regions of the monkey brain, including the hippocampus, hypothalamus, cortex, and striatum, with little or no receptor mRNA detected in either the olfactory tubercle, medulla, cerebellum, or amygdala. The SSTR4 gene maps to human chromosome 20. These findings document the existence of a novel human SSTR gene. Although the hSSTR4 displays an overall deduced amino acid homology of 86% with the recently reported rat homolog [Proc. Natl. Acad. Sci. USA 89:11151-11155 (1992)], the two gene products possess distinctive pharmacological profiles and affinities for the SST agonists SMS 201-995 and MK-678.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100352

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  10 in total

1.  Ligand internalization and recycling by human recombinant somatostatin type 4 (h sst(4)) receptors expressed in CHO-K1 cells.

Authors:  K S Smalley; J A Koenig; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst1 in the somatostatinergic parvocellular neuronal system of the rat hypothalamus.

Authors:  L Helboe; C E Stidsen; M Moller
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

Review 3.  Somatostatin.

Authors:  T Reisine
Journal:  Cell Mol Neurobiol       Date:  1995-12       Impact factor: 5.046

Review 4.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 5.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 6.  Molecular pharmacology of somatostatin receptors.

Authors:  D Hoyer; H Lübbert; C Bruns
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-11       Impact factor: 3.000

7.  In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.

Authors:  I Virgolini; P Angelberger; S Li; Q Yang; A Kurtaran; M Raderer; N Neuhold; K Kaserer; M Leimer; M Peck-Radosavljevic; W Scheithauer; B Niederle; H G Eichler; P Valent
Journal:  Eur J Nucl Med       Date:  1996-10

Review 8.  Drug design at peptide receptors: somatostatin receptor ligands.

Authors:  Jason P Hannon; Caroline Nunn; Barbara Stolz; Christians Bruns; Gisbert Weckbecker; Ian Lewis; Thomas Troxler; Konstanze Hurth; Daniel Hoyer
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

9.  Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

Authors:  M John; W Meyerhof; D Richter; B Waser; J C Schaer; H Scherübl; J Boese-Landgraf; P Neuhaus; C Ziske; K Mölling; E O Riecken; J C Reubi; B Wiedenmann
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

10.  Somatostatin receptor subtypes in neuroendocrine tumor cell lines and tumor tissues.

Authors:  S Jonas; M John; J Boese-Landgraf; R Häring; G Prevost; F Thomas; S Rosewicz; E O Riecken; B Wiedenmann; P Neuhaus
Journal:  Langenbecks Arch Chir       Date:  1995
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.